Dimethaid shareholders elect new board of directors
TORONTO, Sept. 21 /CNW/ - Shareholders of Dimethaid Research Inc. (TSX:
DMX) elected a new board of directors at today's Annual General Meeting.
The new board consists of Daniel H. Chicoine, David A. Copeland, Anthony
E. Dobranowski, Dr. Henrich R.K. Guntermann, Dr. Klaus von Lindeiner, John C.
London and Dr. Jacques Messier.
The Company's auditors Schwartz, Levitsky and Feldman were reappointed
until the next annual meeting of shareholders.
About Dimethaid
Dimethaid Research Inc. is a publicly traded, Canadian, pharmaceutical
company headquartered in Markham, Ontario, with manufacturing facilities in
Varennes, Québec and Wanzleben, Germany. The company develops and
commercializes targeted therapeutic drugs designed to produce minimal side
effects. Dimethaid's two technology platforms focus on transcellular drug
delivery and immune system regulation. Products are aimed at expanding
treatment options in rheumatology, dermatology, oncology, immunology, and the
therapeutic management of chronic viral infections. For more information,
please visit www.dimethaid.com.
This release may contain forward-looking statements, subject to risks and
uncertainties beyond management's control. Actual results could differ
materially from those expressed here. Risk factors are discussed in the
Company's annual information form filed with the securities commissions in
each of the provinces of Canada. The Company undertakes no obligation to
revise forward-looking statements in light of future events. |
